Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...

The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

The FDA expanded the approval of the direct-acting antiviral (DAA) glecaprevir/pibrentasvir (Mavyret), making it the first ...

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis ...

The country has recorded a surge of hepatitis cases, and the alarming situation has called for better clarity in ...

Learn about 5 liver infections that can hide in your body for decades without symptoms. Discover warning signs and prevention ...

AbbVie’s Mavyret receives US FDA label expansion approval for treatment of chronic hepatitis C virus: North Chicago Saturday, June 14, 2025, 11:00 Hrs [IST] AbbVie announced tha ...

The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc’s (NYSE:ABBV) Mavyret ...

Chronic hepatitis B (CHB) is a long-term infection of the liver caused by the hepatitis B virus (HBV). While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the ...

MA, MPH Hepatitis B Coalition of Washington. Every May, we observe Hepatitis Awareness Month — a vital opportunity to educate, advocate, and mobilize ac ...

AbbVie has received approval from the U.S. Food and Drug Administration (FDA) for a label expansion for MAVYRET ...